Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
Rosaria Chilà(Mario Negri Institute for Pharmacological Research), Giovanna Damia(Mario Negri Institute for Pharmacological Research)
Cited by 8
Related Papers
BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models
|Frontiers in Pharmacology|2024|3